Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1] ·  Next »
NCT ID: NCT06231069 Withdrawn - Sarcopenia Clinical Trials

Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults

Start date: January 20, 2030
Phase: N/A
Study type: Interventional

This study aims to elucidate the effects of 12 weeks of novel multi-nutrient supplementation combined with mixed aerobic/resistance exercise training on skeletal muscle function in young adults. It is hypothesized that multi-nutrient supplementation and mixed aerobic/resistance exercise training (AET/RET) will have interactive effects on muscle fitness.

NCT ID: NCT06030284 Withdrawn - Clinical trials for Chronic Intractable Pain

The True Efficacy of Burst Spinal Cord Stimulation in the Management of Intractable Low Back Pain (TRU-BURST)

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this prospective, multi-center, randomized, triple-blind, sham-controlled study with parallel economic evaluation is to test the analgesic superiority of BurstDR-SCS compared to sham stimulation using both traditional patient-reported pain outcome measures and objective physiologic data collected from patient-worn biosensors. The endpoints associated with these objectives will be studied across a follow-up period of 6 months.

NCT ID: NCT06018116 Withdrawn - Clinical trials for Metastatic Urothelial Carcinoma

A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.

CANUCK-01
Start date: November 7, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II, multi-center, placebo-controlled randomized controlled trial of standard of care (SOC) avelumab versus SOC avelumab with bicalutamide for patients with metastatic or locally advanced urothelial carcinoma.

NCT ID: NCT05918250 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.

NCT ID: NCT05830214 Withdrawn - Healthy Clinical Trials

Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS

Start date: January 2024
Phase:
Study type: Observational

This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.

NCT ID: NCT05770427 Withdrawn - Clinical trials for Parent-Child Relations

Evaluating an Online Parenting Intervention in a Community-Based Sample of Parents

Start date: June 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of the online modality of the Make the Connection (MTC) program in a community-based sample of parents not at-risk for parenting difficulties. The main questions it aims to answer are: - Does the MTC online program result in improvements in parent-child bond, parent self-efficacy, parental stress, and parental depression among parents who are not at-risk for parent-child relationship difficulties? - What are some of the barriers, facilitators, perceived benefits and risks to participating in the MTC online program from the perspective of parents? Participants will be asked to complete a pre-intervention questionnaire, will be invited to complete the 8-week MTC online program consisting of a weekly 15-minute module, and will lastly be asked to complete a post-intervention questionnaire.

NCT ID: NCT05696678 Withdrawn - Postoperative Pain Clinical Trials

Improving ObsQoR-11 With Continuous Wound Infusion Versus Intrathecal Morphine After Elective Cesarean Delivery

CIVIMEC
Start date: February 2023
Phase: N/A
Study type: Interventional

The purpose of this prospective randomized double-blinded and controlled study is to evaluate the quality of recovery after elective cesarean delivery using the Obstetric Quality-of-Recovery-11 (ObsQoR-11) score at 24 hours between patients receiving intrathecal morphine (ITM group) compared to patients receiving a ropivacaine continuous wound infusion (CWI group).

NCT ID: NCT05634213 Withdrawn - Cardiac Surgery Clinical Trials

Feasibility of Transepicardial Atrial Injection

Start date: March 1, 2023
Phase: Early Phase 1
Study type: Interventional

Single blind feasibility trial using a binary 'traffic light' design to evaluate the feasibility of injecting normal physiological saline into the atria of patients at the time of clinically indicated open chest cardiac surgery.

NCT ID: NCT05614245 Withdrawn - COVID-19 Clinical Trials

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant

Start date: March 2023
Phase: Phase 1
Study type: Interventional

VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. The trivalent vaccine candidate is designed to induce neutralizing antibody and cell-mediated immune responses against the spike protein of the original strain of SARS-CoV-2 coronavirus, variants and subvariants of SARS-CoV-2 (such as Beta, Delta and Omicron BA.5) and other related coronaviruses that could emerge in the future. VBI-2901e contains two adjuvants: aluminum phosphate and E6020. The role of the adjuvants is to create a stronger immune response to the vaccine. This Phase 1 study will be an open-label study of VBI-2901e comparing three dose levels of the E6020 adjuvant component (1, 3, or 10 µg per dose) in adults 18 to 40 years of age who had previously received two or more vaccinations with licensed COVID-19 vaccine(s). VBI-2901e at each dose level of E6020 will be administered as either a single dose or two-dose regimen. The purpose of the study is to test the safety of VBI-2901e and to learn more about its ability to boost immune responses against SARS-CoV-2 and the two related coronaviruses SARS-CoV-1 and MERS-CoV.

NCT ID: NCT05594667 Withdrawn - Depression Clinical Trials

Effect of SSRIs on Response to Psilocybin Therapy

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups: - Group 1: ≤ 1 year - Group 2: 1 to ≤ 5 years - Group 3: 5 to ≤ 10 years - Group 4: > 10 years